Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D05HDJ
|
|||
Drug Name |
PMID25656651-Compound-20a
|
|||
Drug Type |
Small molecular drug
|
|||
Company |
IRM LLC DING, Qiang SIM, Tae-bo ZHANG, Guobao ADRIAN, Francisco GRAY, Nathanael, S
|
|||
Structure |
Download2D MOL |
|||
Formula |
C18H13F3N6O
|
|||
Canonical SMILES |
C1=CC(=CN=C1)CN2C3=NC=NC(=C3C=N2)NC4=CC=C(C=C4)OC(F)(F)F
|
|||
InChI |
1S/C18H13F3N6O/c19-18(20,21)28-14-5-3-13(4-6-14)26-16-15-9-25-27(17(15)24-11-23-16)10-12-2-1-7-22-8-12/h1-9,11H,10H2,(H,23,24,26)
|
|||
InChIKey |
JOLSWPYDQLCFEP-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Fusion protein Bcr-Abl (Bcr-Abl) | Target Info | Inhibitor | [1] |
Target's Patent Info | Fusion protein Bcr-Abl (Bcr-Abl) | Target's Patent Info | [1] |
References | Top | |||
---|---|---|---|---|
REF 1 | Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.